Keywords: Sanofi, Merck KGaA, Idera Pharma, Multaq, IMO-2055, Atrial fibrilation, Cancer

CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns

Article | 08 July 2011

Print This

In two clinical disappointments announced yesterday, French drug major Sanofi (Euronext: SAN) and Germany’s Merck KGaA (MRK: DE) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in